OTCPK:NMTC

Stock Analysis Report

NeuroOne Medical Technologies

Executive Summary

NeuroOne Medical Technologies Corporation, an early-stage medical technology company, focuses on the development and commercialization of thin film electrode technology.

Snowflake

Fundamentals

Worrying balance sheet with weak fundamentals.

Risks

  • NeuroOne Medical Technologies has significant price volatility in the past 3 months.
  • NeuroOne Medical Technologies is not covered by any analysts.

Share Price & News

How has NeuroOne Medical Technologies's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-6.5%

NMTC

1.1%

US Medical Equipment

-0.5%

US Market


1 Year Return

-56.6%

NMTC

7.9%

US Medical Equipment

0.9%

US Market

NMTC underperformed the Medical Equipment industry which returned 9.7% over the past year.

NMTC underperformed the Market in United States of America which returned 0.7% over the past year.


Share holder returns

NMTCIndustryMarket
7 Day-6.5%1.1%-0.5%
30 Day-11.9%3.1%4.8%
90 Day-44.9%3.6%2.3%
1 Year-56.6%-56.6%8.8%7.9%3.1%0.9%
3 Yearn/a70.9%65.8%45.5%36.0%
5 Yearn/a139.2%112.0%62.5%44.7%

Price Volatility Vs. Market

How volatile is NeuroOne Medical Technologies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is NeuroOne Medical Technologies undervalued based on future cash flows and its price relative to the stock market?


In this section, we usually try to help investors determine whether NeuroOne Medical Technologies is trading at an attractive price based on the cash flow it is expected to produce in the future. But as NeuroOne Medical Technologies has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of NMTC’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through NeuroOne Medical Technologies regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is NeuroOne Medical Technologies expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

22.5%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as NeuroOne Medical Technologies has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of NMTC’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access NeuroOne Medical Technologies's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has NeuroOne Medical Technologies performed over the past 5 years?

-58.1%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

NeuroOne Medical Technologies does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare NeuroOne Medical Technologies's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare NeuroOne Medical Technologies's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if NeuroOne Medical Technologies has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.


Return on Assets

It is difficult to establish if NeuroOne Medical Technologies has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if NeuroOne Medical Technologies improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.


Next Steps

Financial Health

How is NeuroOne Medical Technologies's financial position?


Financial Position Analysis

NeuroOne Medical Technologies's short term (1 year) commitments are greater than its holdings of cash and other short term assets.

NeuroOne Medical Technologies has no long term commitments.


Debt to Equity History and Analysis

NeuroOne Medical Technologies has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.

Irrelevant to check if NeuroOne Medical Technologies's debt level has increased considering it has negative shareholder equity.


Balance Sheet

Low level of unsold assets.

NeuroOne Medical Technologies has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

NeuroOne Medical Technologies has less than a year of cash runway based on current free cash flow.

NeuroOne Medical Technologies has less than a year of cash runway if free cash flow continues to grow at historical rates of 72.3% each year.


Next Steps

Dividend

What is NeuroOne Medical Technologies's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate NeuroOne Medical Technologies's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate NeuroOne Medical Technologies's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as NeuroOne Medical Technologies has not reported any payouts.

Unable to verify if NeuroOne Medical Technologies's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as NeuroOne Medical Technologies has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of NeuroOne Medical Technologies's salary, the management and board of directors tenure and is there insider trading?

1.4yrs

Average management tenure


CEO

Dave Rosa (55yo)

2.2yrs

Tenure

0

Mr. David A. Rosa, also known as Dave, M.D., has been Chief Executive Officer, President & Director at NeuroOne Medical Technologies Corporation since July 21, 2017. Mr. Rosa served as the Chief Executive  ...


Management Age and Tenure

1.4yrs

Average Tenure

55yo

Average Age

The average tenure for the NeuroOne Medical Technologies management team is less than 2 years, this suggests a new team.


Board Age and Tenure

2.1yrs

Average Tenure

56.5yo

Average Age

The average tenure for the NeuroOne Medical Technologies board of directors is less than 3 years, this suggests a new board.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Steve Mertens (56yo)

    Chief Technology Officer

    • Tenure: 0.4yrs
  • Dave Rosa (55yo)

    CEO, President & Director

    • Tenure: 2.2yrs
  • Mark Christianson (52yo)

    Vice President of Business Development & Marketing

    • Tenure: 2.2yrs
    • Compensation: US$194.18k
  • Scott Heuler (55yo)

    Vice President of Sales

    • Tenure: 0.7yrs

Board Members

  • Jeff Mathiesen (58yo)

    Independent Director

    • Tenure: 2.1yrs
    • Compensation: US$46.88k
  • Suraj Kalia (47yo)

    Independent Director

    • Tenure: 2.1yrs
    • Compensation: US$41.25k
  • Dave Rosa (55yo)

    CEO, President & Director

    • Tenure: 2.2yrs
  • Joseph Madsen

    Member of Scientific Advisory Board

    • Tenure: 1.3yrs
  • Paul Buckman (63yo)

    Chairman of the Board

    • Tenure: 2.1yrs
    • Compensation: US$78.75k
  • Greg Worrell

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Jamie Van Gompel

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Jorge Gonzalez

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Greg Esper

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Kip Ludwig

    Chairman of Artificial Intelligence Advisory Board

    • Tenure: 1yrs

Company Information

NeuroOne Medical Technologies Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: NeuroOne Medical Technologies Corporation
  • Ticker: NMTC
  • Exchange: OTCPK
  • Founded:
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$29.011m
  • Shares outstanding: 13.49m
  • Website: https://www.neurooneinc.com

Number of Employees


Location

  • NeuroOne Medical Technologies Corporation
  • 10901 Red Circle Drive
  • Suite 150
  • Minnetonka
  • Minnesota
  • 55343
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
NMTCOTCPK (Pink Sheets LLC)YesCommon StockUSUSDJul 2017

Biography

NeuroOne Medical Technologies Corporation, an early-stage medical technology company, focuses on the development and commercialization of thin film electrode technology. The company develops cortical and s ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/24 00:50
End of Day Share Price2019/09/23 00:00
Earnings2019/06/30
Annual Earnings2018/09/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.